Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#3057 Epidemiological Features of Patients with NeuroEndocrine Neoplasms (NENs): Preliminary Results of an Observational Study by the Hellenic Society of Medical Oncology (HeSMO)

Introduction: NENs are rare tumors and can grow in almost all tissues. Regardless histological, molecular and imaging characteristics that are indicative of the primary origin, a significant percentage remain of unknown primary.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Koumarianou A

Authors: Koumarianou A, Tsoukalas N, Syrigos K, Demiri S, Ziras N,

Keywords: NeuroEndocrine Neoplasms (NENs), epidemiological features, registry, diagnosis, Hellenic Society of Medical Oncology (HeSMO),

#2242 Diagnostic Utility of Ki-67 as a Mean to Predict the Uptake of Functional Imaging Modalities in Patients with Neuroendocrine Neoplasms

Introduction: Functional imaging with FDG-PET and somatostatin receptors scintigraphy (SRS), play a key role in the diagnosis, treatment and follow-up of patients with neuroendocrine neoplasms (NENs). The proliferative index, ki67, is a reliable pathological marker for grading.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Mavroeidi V

Authors: Liotsou T, Mavroeidi V, Alexandraki K, Stefanoyiannis A, Thomas D,

Keywords: SRS, PET-FDG, ki-67, NENs,

#2060 Peptide Receptor Radionuclide Therapy (PRRT) in 35 Patients with Metastatic Neuroendocrine Neoplasms (NENs): Overall Response and Toxicity

Introduction: Metastatic or inoperable NeuroEndocrine Neoplasms (NENs) are unresponsive to chemotherapy and targeted therapies. An emerging option is PRRT.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Liotsou T

Authors: Liotsou T, Stefanoyiannis A, Alexandraki K, Koumarianou A, Angelousi A,

Keywords: NENs, PRRT,

#1935 Prevalence of Pancreatic Neuroendocrine Neoplasms with Serotonin Secretion

Introduction: Pancreatic neuroendocrine neoplasms (pNENs) are rare neoplasms and represent 1-2% of all pancreatic neoplasms. These tumors can secrete a variety of hormonally active substances producing distinct clinical symptoms, or can be clinically non-functioning. Pancreatic NENs that secrete serotonin are extremely rare, but their prevalence has not been explored adequately.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Tsoukalas N

Authors: Tsoukalas N, Alexandraki K, Mavroeidi V, Chatzellis E, Tsoli M,

Keywords: serotonin-producing pNEN, 5-HIAA, prognosis,

#1764 Use of Tyrosine-Kinase Inhibitors in Medullary Thyroid Carcinoma: An Institutional Experience

Introduction: Medullary thyroid cancer (MTC) comprises 4% of thyroid tumors. 7-23% of patients (pts) have metastases at diagnosis. In some cases metastatic disease follows an indolent course, and in others it progresses rapidly, requiring systemic treatment. Tyrosine-kinase inhibitors (TKI) have demonstrated a median progression-free survival (PFS) of 11 months.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Luca R

Authors: Luca R, O'Connor J, Falco A, Do Pico F, Tsou F,

Keywords: TNE, TKI,

Abstract Submissions in 2023

Abstract submissions for 2023 will open in September 2022!


The 20th Annual ENETS Conference in 2023 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.


Participants of the ENETS Conferences in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.